ALLMedicine™ Hidradenitis Suppurativa Center
Research & Reviews 1,632 results
https://doi.org/10.12788/jfp.0525
The Journal of Family Practice; Marti-Amarista C, Rali M
Feb 4th, 2023 - Early diagnosis and treatment of hidradenitis suppurativa is key to avoiding severe disease and minimizing its negative psychological impact.
https://doi.org/10.1093/bjd/ljac120
The British Journal of Dermatology; Steyn M, Ayis S et. al.
Feb 4th, 2023 - Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting.|2023|Steyn M,Ayis S,O'Connor J,Lakhan MK,Ferguson F,|
https://clinicaltrials.gov/ct2/show/NCT04242446
Feb 3rd, 2023 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
https://clinicaltrials.gov/ct2/show/NCT04901195
Feb 3rd, 2023 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
https://doi.org/10.1093/ced/llac023
Clinical and Experimental Dermatology; Oktem A, Rasulova G et. al.
Feb 3rd, 2023 - Successful treatment with anakinra in generalized spiculated porokeratosis and severe hidradenitis suppurativa in a patient with MVK and MEFV mutations.|2023|Oktem A,Rasulova G,Cavdarli B,Bostanci S,Heper A,|
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.
Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...
Drugs 1 results see all →
Clinicaltrials.gov 147 results
https://clinicaltrials.gov/ct2/show/NCT04901195
Feb 3rd, 2023 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
https://clinicaltrials.gov/ct2/show/NCT04242446
Feb 3rd, 2023 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
https://clinicaltrials.gov/ct2/show/NCT05710393
Feb 2nd, 2023 - Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease characterized by multiple abscesses located predominantly in areas such as armpit, genital, pelvic, and perineum. It is considered an orphan disease of unknown origin and no exi...
https://clinicaltrials.gov/ct2/show/NCT04354012
Feb 2nd, 2023 - Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory disease most frequently affecting the axilla, groin, and inframammary regions. Symptoms include nodules, abscesses, sinus tract formation, malodorous drainage, and scarring. ...
https://clinicaltrials.gov/ct2/show/NCT05322473
Feb 2nd, 2023 - This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
News 271 results
https://www.mdedge.com/familymedicine/article/260934/dermatology/scalp-ridges
MDedge Family Medicine;
Jan 31st, 2023 - The gyrate or cerebriform pattern of inflammatory, often pus-filled, subcutaneous tracts of the scalp pointed to a diagnosis of dissecting cellulitis. This patient did not have the fluctuant tracts frequently seen in more active disease but did ha.
https://www.medpagetoday.com/rheumatology/arthritis/102660
Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...
https://www.mdedge.com/familymedicine/article/260048/dermatology/practical-guide-hidradenitis-suppurativa
MDedge Family Medicine; Cristina Marti-Amarista, MD, Mayur Rali, MD
Dec 12th, 2022 - Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil disease, is a chronic, recurrent, inflammatory occlusive disease affecting the terminal follicular epithelium in apocrine gland–bearing skin areas. 1 HS manifests as painful nodu.
https://www.mdedge.com/dermatology/article/259896/medical-dermatology/consider-quality-life-comorbidities-hidradenitis
Heidi Splete
Dec 2nd, 2022 - LAS VEGAS – The delay in the diagnosis of hidradenitis suppurativa (HS) often ranges from 7 to 10 years, which results in increased morbidity and disease severity, and an extended impact on quality of life, Robert G. Micheletti, MD, said in a pres.
https://www.mdedge.com/dermatology/article/259857/medical-dermatology/hs-treated-eds-not-followed-derm-clinics-study-finds
Lorraine L. Janeczko, MPH
Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th.